claim: johnson & johnson announces instead of rolling submission for its single-dose janssen covid-19 vaccine candidate with the european medicines agency
evidence_1: the emas committee for medicinal products for human use (chmp) enabled a rolling review of the investigational single-dose janssen covid-19 vaccine candidate based principally on positive non-clinical data showing that the vaccine candidate elicits a robust immune response, as demonstrated by neutralizing antibodies.", "134 janssen-cilag international n.v., part of the janssen pharmaceutical companies of johnson & johnson, has initiated a rolling submission with the european medicines agency (ema) for its investigational single-dose vaccine candidate for the prevention of covid-19.", 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  "janssens investigational covid-19 vaccine candidate the investigational janssen covid-19 vaccine candidate leverages the companys advac® vaccine platform, which was also used to develop and manufacture janssens european commission-approved ebola vaccine regimen and construct its zika, rsv, and hiv investigational vaccine candidates.", "in addition to the ema, janssen is in discussions with other regulatory authorities worldwide, as it prepares to initiate regulatory review processes for use of its investigational single-dose covid-19 vaccine candidate during the pandemic response period."
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  )